13-azaprostanoic acid

Known as: Cyclopentaneheptanoic acid, 2-(heptylamino)-, (1S-trans)- 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1979-2005
0246819792005

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
BACKGROUND Patients treated with aspirin may have a reduced sensitivity to its antiplatelet effect. The mechanism accounting for… (More)
Is this relevant?
1984
1984
Isometric contractions in vitro of helically cut strips of canine mesenteric arteries (O.D. = 0.6-1 mm) were recorded in the… (More)
Is this relevant?
1984
1984
The present study evaluated the direct involvement of thromboxane A2/prostaglandin H2 (TXA2/PGH2) in the process of thrombus… (More)
Is this relevant?
1983
1983
In the present study we characterized the interaction between the thromboxane A2/prostaglandin H2 antagonist, trans-13… (More)
Is this relevant?
1983
1983
The effects of 13-azaprostanoic acid (13-APA) were studied during acute myocardial ischemia in cats and in rabbit sudden death… (More)
Is this relevant?
1983
1983
In the present study we investigated the ability of the arachidonic acid metabolites, prostaglandin H2 and thromboxane A2, to… (More)
Is this relevant?
1982
1982
The specific thromboxane A2/prostaglandin H2 (TXA2/PGH2) antagonist 13-azaprostanoic acid (13-APA) reverses platelet aggregation… (More)
Is this relevant?
Highly Cited
1981
Highly Cited
1981
Platelets obtained from some diabetic patients show enhanced in vitro platelet aggregation. This study sought to determine… (More)
Is this relevant?
1980
1980
The potential deleterious role of the proaggregatory vasoconstrictor, thromboxane A(2), in endotoxic shock was investigated in… (More)
  • figure 1
  • figure 2
  • table I
Is this relevant?
1979
1979
A newly synthesized 13-aza derivative of prostanoic acid (13-APA) specifically inhibited human platelet aggregation induced by… (More)
Is this relevant?